Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments
Background Whereas safe, curative treatments for hepatitis C virus (HCV) have been available since 2015, there are still 58 million infected persons worldwide, and global elimination may require new paradigms. We sought to understand the acceptability of approaches to long-acting HCV treatment....
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Oxford University Press
2024
|
| Online Access: | https://hdl.handle.net/1721.1/155049 |
| _version_ | 1811074356354220032 |
|---|---|
| author | Weld, Ethel D Astemborski, Jacqueline Kirk, Gregory D Sulkowski, Mark S Katz, Stephanie Rothman, Richard Solomon, Sunil S Matthews, Gail V Hsieh, Yu Hsiang Verma, Malvika Traverso, Giovanni Swindells, Susan Owen, Andrew Feld, Jordan Flexner, Charles Mehta, Shruti H Thomas, David L |
| author_facet | Weld, Ethel D Astemborski, Jacqueline Kirk, Gregory D Sulkowski, Mark S Katz, Stephanie Rothman, Richard Solomon, Sunil S Matthews, Gail V Hsieh, Yu Hsiang Verma, Malvika Traverso, Giovanni Swindells, Susan Owen, Andrew Feld, Jordan Flexner, Charles Mehta, Shruti H Thomas, David L |
| author_sort | Weld, Ethel D |
| collection | MIT |
| description | Background
Whereas safe, curative treatments for hepatitis C virus (HCV) have been available since 2015, there are still 58 million infected persons worldwide, and global elimination may require new paradigms. We sought to understand the acceptability of approaches to long-acting HCV treatment.
Methods
A cross-sectional, 43-question survey was administered to 1457 individuals with or at risk of HCV at 28 sites in 9 countries to assess comparative interest in a variety of long-acting strategies in comparison with oral pills.
Results
Among HCV-positive participants, 37.7% most preferred an injection, 5.6% an implant, and 6% a gastric residence device, as compared with 50.8% who stated they would most prefer taking 1–3 pills per day. When compared directly to taking pills, differences were observed in the relative preference for an injection based on age (P<.001), location (P<.001), and prior receipt of HCV treatment (P=.005) but not sex. When an implant was compared with pills, greater preference was represented by women (P=.01) and adults of younger ages (P=.01 per 5 years). Among participants without HCV, 49.5% believed that injections are stronger than pills and 34.7% preferred taking injections to pills. Among those at-risk participants who had received injectable medications in the past, 123 of 137 (89.8%) expressed willingness to receive one in the future.
Conclusions
These data point to high acceptability of long-acting treatments, which for a substantial minority might even be preferred to pills for the treatment of HCV infection. Long-acting treatments for HCV infection might contribute to global efforts to eliminate hepatitis C. |
| first_indexed | 2024-09-23T09:47:46Z |
| format | Article |
| id | mit-1721.1/155049 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T09:47:46Z |
| publishDate | 2024 |
| publisher | Oxford University Press |
| record_format | dspace |
| spelling | mit-1721.1/1550492024-05-24T03:49:10Z Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments Weld, Ethel D Astemborski, Jacqueline Kirk, Gregory D Sulkowski, Mark S Katz, Stephanie Rothman, Richard Solomon, Sunil S Matthews, Gail V Hsieh, Yu Hsiang Verma, Malvika Traverso, Giovanni Swindells, Susan Owen, Andrew Feld, Jordan Flexner, Charles Mehta, Shruti H Thomas, David L Background Whereas safe, curative treatments for hepatitis C virus (HCV) have been available since 2015, there are still 58 million infected persons worldwide, and global elimination may require new paradigms. We sought to understand the acceptability of approaches to long-acting HCV treatment. Methods A cross-sectional, 43-question survey was administered to 1457 individuals with or at risk of HCV at 28 sites in 9 countries to assess comparative interest in a variety of long-acting strategies in comparison with oral pills. Results Among HCV-positive participants, 37.7% most preferred an injection, 5.6% an implant, and 6% a gastric residence device, as compared with 50.8% who stated they would most prefer taking 1–3 pills per day. When compared directly to taking pills, differences were observed in the relative preference for an injection based on age (P<.001), location (P<.001), and prior receipt of HCV treatment (P=.005) but not sex. When an implant was compared with pills, greater preference was represented by women (P=.01) and adults of younger ages (P=.01 per 5 years). Among participants without HCV, 49.5% believed that injections are stronger than pills and 34.7% preferred taking injections to pills. Among those at-risk participants who had received injectable medications in the past, 123 of 137 (89.8%) expressed willingness to receive one in the future. Conclusions These data point to high acceptability of long-acting treatments, which for a substantial minority might even be preferred to pills for the treatment of HCV infection. Long-acting treatments for HCV infection might contribute to global efforts to eliminate hepatitis C. 2024-05-23T21:10:41Z 2024-05-23T21:10:41Z 2021-10-26 2024-05-23T20:40:46Z Article http://purl.org/eprint/type/JournalArticle 1058-4838 1537-6591 https://hdl.handle.net/1721.1/155049 thel D Weld, Jacqueline Astemborski, Gregory D Kirk, Mark S Sulkowski, Stephanie Katz, Richard Rothman, Sunil S Solomon, Gail V Matthews, Yu Hsiang Hsieh, Malvika Verma, Giovanni Traverso, Susan Swindells, Andrew Owen, Jordan Feld, Charles Flexner, Shruti H Mehta, David L Thomas, Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments, Clinical Infectious Diseases, Volume 75, Issue 1, 1 July 2022, Pages 3–10. en 10.1093/cid/ciab913 Clinical Infectious Diseases Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. application/pdf Oxford University Press Oxford University Press |
| spellingShingle | Weld, Ethel D Astemborski, Jacqueline Kirk, Gregory D Sulkowski, Mark S Katz, Stephanie Rothman, Richard Solomon, Sunil S Matthews, Gail V Hsieh, Yu Hsiang Verma, Malvika Traverso, Giovanni Swindells, Susan Owen, Andrew Feld, Jordan Flexner, Charles Mehta, Shruti H Thomas, David L Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments |
| title | Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments |
| title_full | Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments |
| title_fullStr | Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments |
| title_full_unstemmed | Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments |
| title_short | Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments |
| title_sort | preferences of persons with or at risk for hepatitis c for long acting treatments |
| url | https://hdl.handle.net/1721.1/155049 |
| work_keys_str_mv | AT weldetheld preferencesofpersonswithoratriskforhepatitiscforlongactingtreatments AT astemborskijacqueline preferencesofpersonswithoratriskforhepatitiscforlongactingtreatments AT kirkgregoryd preferencesofpersonswithoratriskforhepatitiscforlongactingtreatments AT sulkowskimarks preferencesofpersonswithoratriskforhepatitiscforlongactingtreatments AT katzstephanie preferencesofpersonswithoratriskforhepatitiscforlongactingtreatments AT rothmanrichard preferencesofpersonswithoratriskforhepatitiscforlongactingtreatments AT solomonsunils preferencesofpersonswithoratriskforhepatitiscforlongactingtreatments AT matthewsgailv preferencesofpersonswithoratriskforhepatitiscforlongactingtreatments AT hsiehyuhsiang preferencesofpersonswithoratriskforhepatitiscforlongactingtreatments AT vermamalvika preferencesofpersonswithoratriskforhepatitiscforlongactingtreatments AT traversogiovanni preferencesofpersonswithoratriskforhepatitiscforlongactingtreatments AT swindellssusan preferencesofpersonswithoratriskforhepatitiscforlongactingtreatments AT owenandrew preferencesofpersonswithoratriskforhepatitiscforlongactingtreatments AT feldjordan preferencesofpersonswithoratriskforhepatitiscforlongactingtreatments AT flexnercharles preferencesofpersonswithoratriskforhepatitiscforlongactingtreatments AT mehtashrutih preferencesofpersonswithoratriskforhepatitiscforlongactingtreatments AT thomasdavidl preferencesofpersonswithoratriskforhepatitiscforlongactingtreatments |